Mechanisms of Subcutaneous Absorption of Rituximab in Rats
Open Access
- 5 November 2012
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 41 (1), 248-255
- https://doi.org/10.1124/dmd.112.048496
Abstract
Absorption of monoclonal antibodies (mAbs) after s.c. injection results from the interplay among several kinetic processes. The aims of this study were to investigate the absorption mechanisms of rituximab in rats by using slow s.c. infusion and coadministration with nonspecific IgG or hyaluronidase, and to evaluate the predictive performance of the pharmacokinetic model previously developed to describe the nonlinear absorption behavior of mAbs. Rituximab serum concentrations were measured after s.c. coadministration with nonspecific IgG and hyaluronidase to rats. Several dose levels and different injection sites were evaluated. For the back site, 6.5- and 2.6-fold decreases in the area under the concentration-time curve were obtained after coadministration with IgG for 1 and 10 mg/kg doses compared with administration of rituximab alone. For the abdomen, only a minor reduction in concentrations was observed. Hyaluronidase increased the rate of s.c. absorption and the bioavailability (1.9- and 1.6-fold for the back and the abdomen injection of 10 mg/kg). Our previously established pharmacokinetic model provided excellent predictions of the effect of nonspecific IgG on rituximab absorption. In conclusion, the magnitude of the effect of absorption modifiers is dependent on the site of injection and the dose level of rituximab. Pharmacokinetic profiles further support the hypothesis that neonatal Fc receptor–mediated transport is a major determinant of s.c. absorption of mAbs.Keywords
This publication has 28 references indexed in Scilit:
- Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeysmAbs, 2012
- Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in micemAbs, 2012
- Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus MonkeysDrug Metabolism and Disposition, 2010
- Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemiaHaematologica, 2009
- Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout miceJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExpert Opinion on Drug Delivery, 2007
- A recombinant human enzyme for enhanced interstitial transport of therapeuticsJournal of Controlled Release, 2006
- The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thighClinical Endocrinology, 1991
- The lymphatic route—III. Pharmacokinetics of human natural interferon-β injected with albumin as a retarder in rabbitsGeneral Pharmacology: The Vascular System, 1986
- The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasmaCellular and Molecular Life Sciences, 1986